Chargement en cours...
Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial
BACKGROUND: Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical studies. METHODOLOGY: We conducted two...
Enregistré dans:
| Publié dans: | PLoS Negl Trop Dis |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5026339/ https://ncbi.nlm.nih.gov/pubmed/27636542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0005008 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|